Clinical trials: Obstructive Lung Disease
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week…
- Trial name
- OPTIMIZE (NCT02165826)
- Testing
- Roflumilast, Standard of Care COPD Treatment
- Where
- 2 sites in Slovakia
- Volunteers
- 1,323 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive (COPD)
Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece
Chronic obstructive pulmonary disease (COPD) is a debilitating and progressive respiratory condition characterized by irreversible airflow limitation.
- Trial name
- TRIAENA (NCT05915182)
- Testing
- Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler
- Where
- 15 sites in Greece
- Volunteers
- 212 people
- Sponsor
- AstraZeneca
Asthma
Study in Mild Asthmatic Patients
The purpose of this study is to determine the safety and usefulness of GSK2190915 in asthmatic patients who develop asthma symptoms following being challenged.
- Trial name
- NCT00748306
- Testing
- GSK2190915 - 100mcg
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Therapeutic Effect of PBF-680 in Patients With COPD
The purpose of the study is to investigate the effect of PBF-680 on the chronic inflammation and the lung function of patients with COPD on top of the standard medication.
- Trial name
- Respire (NCT05262218)
- Testing
- PBF-680 10mg
- Where
- 7 sites in Spain
- Volunteers
- 174 people
- Sponsor
- Palobiofarma SL
Pulmonary Disease, Chronic Obstructive, COPD
Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)
The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with COPD.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00396604
- Testing
- indacaterol maleate
- Where
- Belgium
- Volunteers
- 51 people
- Sponsor
- Novartis
Asthma
Effect of Ectoin® Inhalation Solution on Subjects With Mild Bronchial Asthma
In this single center, dose finding, safety study the effect of inhaled Ectoin® inhalation solution will be investigated in subjects with mild bronchial asthma.
- Trial name
- NCT01478152
- Testing
- Drug-like Medical Device: Ectoin Inhalation Solution
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Bitop AG
Asthma
To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study
This is a single blind, single dose, crossover study to investigate the relative efficacy of terbutaline Turbuhaler® 0.4 mg in relation to salbutamol pressurized Metered Dose Inhaler (pMDI) 200 μg in Japanese adult asthmatic…
- Trial name
- NCT01096017
- Testing
- Terbutaline Turbuhaler®, Salbutamol pMDI
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Bronchospasm, Activity/Exercise Induced Bronchospasm
A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
During this study, your child will need to attend up to 5 office visits and maintain regular telephone contact with the clinic. Certain office visits will include physical exams, medical history review, exercise challenge test…
- Trial name
- NCT00118716
- Testing
- Fluticasone propionate/salmeterol, Fluticasone Propionate
- Where
- 50 sites in United States
- Volunteers
- 248 people
- Sponsor
- GlaxoSmithKline
Asthma (Diagnosis)
ADO-5030 in Bronchoconstriction Challenge, Phase 1b
This is a Phase 1 study to learn about the safety and pharmacokinetics of the study drug in patients with asthma and whether the study drug has effect during a respiratory challenge.
- Trial name
- NCT07281274
- Testing
- ADO-5030
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Adovate
Asthma
The Asthma Breathing Record Study
The study involves a new device, called 'N-Tidal C', which uses a method that has the potential to predict when asthma attacks are about to happen. The device works by accurately measuring an individual's exhaled CO2 waveform.
- Trial name
- ABRS (NCT04504838)
- Where
- United Kingdom
- Volunteers
- 124 people
- Sponsor
- TidalSense
Pulmonary Disease, Chronic Obstructive
A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COPD is characterized by an airflow limitation, which is not fully reversible, usually progressive and accompanied by chronic cough, sputum production and dyspnea, which can be a major cause of disability and anxiety associated…
- Trial name
- NCT03034915
- Testing
- UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS
- Where
- 212 sites in United States, Argentina and 10 more
- Volunteers
- 2,696 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients
This is an open-label, randomized, cross-over, active-controlled study to evaluate the efficacy and safety effects using Meptin® Swinghaler and Berotec N® Metered Aerosol in stable asthma patients
- Trial name
- NCT01095016
- Testing
- Meptin swinghaler, Berotec
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Chronic Obstructive Pulmonary Disease
Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162
Pulmonary administered anticholinergic agents have shown their importance in the chronic obstructive pulmonary disease (COPD) management to reduce morbidity, disability and mortality.
- Trial name
- NCT01348555
- Testing
- Bronchodilatator
- Where
- 2 sites in Belgium, France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Asthma
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).
The aim of the study is to assess and compare efficacy and safety of BI 54903 at three different dosages (b.i.d)., fluticasone propionate hydrofluoroalkane (HFA) metered dose inhaler (MDI) at a dose of 440 mcg b.i.d and low dose…
- Trial name
- NCT01396278
- Testing
- Fluticasone propionate, BI 54903
- Where
- 37 sites in United States
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Asthma
Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics
This study is designed to evaluate the repeat-dose safety and effectiveness of a bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11 years with asthma.
- Trial name
- NCT00308685
- Testing
- Albuterol
- Where
- 14 sites in United States
- Volunteers
- 95 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease
Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice
- Trial name
- NCT02236715
- Testing
- Atrovent®
- Volunteers
- 1,039 people
- Sponsor
- Boehringer Ingelheim
Asthma
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe…
- Trial name
- NCT00529529
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 126 sites in United States, Argentina and 10 more
- Volunteers
- 805 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist (LABA)/ inhaled corticosteroid (ICS) combination product on protection from…
- Trial name
- NCT01128569
- Testing
- Fluticasone Furoate, FF/Vilanterol (VI; GW642444M)
- Where
- 4 sites in Germany, New Zealand and 1 more
- Volunteers
- 52 people
- Sponsor
- GlaxoSmithKline
Asthma, Mild Asthma
Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma
This study will evaluate the efficacy and safety of GSK256066 in the treatment of subjects with mild bronchial asthma, using a number of clinical and biological markers of efficacy.
- Trial name
- NCT00380354
- Testing
- GSK256066
- Where
- 2 sites in United Kingdom
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.